A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer

This Phase Ib study tests the safety and early effectiveness of HC010 — a new experimental drug — combined with standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) or small cell lung cancer that has not responded to prior treatments. **You may be eligible if...** - You have confirmed advanced or metastatic solid tumors (dose-finding phase) or specifically NSCLC or extensive small cell lung cancer (expansion phase) that cannot be surgically removed - Your NSCLC either has no targeted gene mutations, has EGFR mutations that progressed on targeted therapy, or is first-line treatment eligible - You have at least one measurable tumor lesion - Your overall health status is good (ECOG 0–1) - Your expected survival is at least 3 months - Your organ function is within acceptable ranges **You may NOT be eligible if...** - Your only measurable lesion is in the brain - You have had serious side effects from prior immunotherapy - You are pregnant or breastfeeding - You have uncontrolled infections, severe heart conditions, or other serious illnesses Talk to your doctor to see if this trial is right for you.